Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Context: Cushing syndrome (CS) is a rare and serious disease with high mortality. Patients are often diagnosed late in the course of the disease. Objective: This work investigated whether defined patient populations should be screened outside the at-risk populations defined in current guidelines. Methods: As part of the prospective German Cushing registry, we studied 377 patients with suspected CS. The chief complaint for CS referral was documented. Using urinary free cortisol, late-night salivary cortisol, and the 1-mg dexamethasone suppression test as well as long-term clinical observation, CS was confirmed in 93 patients and ruled out for the remaining 284. Results: Patients were referred for 18 key symptoms, of which 5 were more common in patients with CS than in those in whom CS was ruled out: osteoporosis (8% vs 2%; P = .02), adrenal incidentaloma (17% vs 8%, P = 0.01), metabolic syndrome (11% vs 4%; P = .02), myopathy (10% vs 2%; P < .001), and presence of multiple symptoms (16% vs 1%; P < .001). Obesity was more common in patients in whom CS was ruled out (30% vs 4%, P < .001), but recent weight gain was prominent in those with CS. A total of 68 of 93 patients with CS (73%) had typical chief complaints, as did 106 of 284 of patients with ruled-out CS status (37%) according to the Endocrine Society practice guideline 2008. Conclusion: The 2008 Endocrine Society Practice guideline for screening and diagnosis of CS defined at-risk populations that should undergo testing. These recommendations are still valid in 2022.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These challenges often lead to delayed diagnosis, contributing to increased morbidity and mortality (48-50, 53).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“The diagnosis of endogenous CS can be challenging due to overlap with common conditions, highly variable clinical features, and challenges in appropriately interpreting biochemical screening and diagnostic tests (11, 48-52).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 3×
“Standard biochemical screening was performed according to guidelines (26, 31), including a sample of 24-hour urine cortisol, late-night salivary cortisol, and 1-mg low-dose dexamethasone suppression test in all patients.”
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · cited 2×
“Other suggested at-risk populations might be patients with hypogonadotropic hypo-gonadism (22), young patients with osteoporosis and vertebral or rib fractures (22), patients with central obesity and clinical signs for CS (22), and with adrenal incidentaloma (23, 24).”
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationDepressive disorders in Europe: prevalence figures from the ODIN study
Ayuso-Mateos, J. L., Vázquez-Barquero, J. L., Dowrick, C., Lehtinen, V., Dalgard, O. S., Casey, P., Wilkinson, C., Lasa, L., Page, H., Dunn, G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.308 · Cited by 564 · cited 2×
“The BMI of patients that presented with weight gain/obesity was higher in the ruled-out group than in patients with CS (38 [29–43] vs 33 [26–36]; P = not significant).”
OMURA, M., SAITO, J., YAMAGUCHI, K., KAKUTA, Y., & NISHIKAWA, T. (2004) · Hypertension Research · doi:10.1291/hypres.27.193 · Cited by 562
Anderson, G. H., Blakeman, N., & Streeten, D. H. P. (1994) · Journal of Hypertension · doi:10.1097/00004872-199405000-00015 · Cited by 403
ROSS, E. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92749-0 · Cited by 390 · cited 1×
“The low incidence of CS and the clinical overlap with pseudo-Cushing states (9), that is, patients with metabolic syndrome or polycystic ovary syndrome (PCOS) (5), can delay a definitive diagnosis and treatment, resulting in increased morbidity and mortality among patients (10-12).”
Cited by
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Self-citationAn individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
Nieman, L. K., Castinetti, F., Newell-Price, J. D. C., Valassi, E., Drouin, J., Takahashi, Y., & Lacroix, A. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00588-w · Cited by 88
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, J. B., Kahn, S. E., Aroda, V. R., Auchus, R. J., Bailey, T. S., Bancos, I., Busch, R. S., Christofides, E. A., DeFronzo, R. A., Eilerman, B., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2841 · Cited by 46
Vogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
Metadata
- Authors
- Braun, L. T., Vogel, F., Zopp, S., Marchant Seiter, T., Rubinstein, G., Berr, C. M., Künzel, H., Beuschlein, F., & Reincke, M.
- Affiliations
- LMU Klinikum (DE)
- Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität München , 80336 Munich , Germany
- University of Augsburg (DE)
- University of Zurich (CH)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-06-22
- Volume
- 107
- Issue
- 9
- Pages
- e3723-e3730
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9387700
- OpenAlex
- W4283326364
- Semantic Scholar
- 1ebd379713fc3fe3b50a5c6191835a65c5fd716a
- Cited by
- 52
- References
- 51
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 14 · 2023: 11 · 2022: 4
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (acceptedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Deutsche Forschungsgemeinschaft (314061271-TRR 205)
- Clinician Scientist Program RISE
- Else-Kröner-Fresenius Stiftung
- Eva Luise und Horst Köhler Stiftung
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, screening, vulnerable populations, chief complaint, urinary free cortisol, late-night salivary cortisol, dexamethasone suppression test, adrenal incidentaloma, osteoporosis, metabolic syndrome, obesity, myopathy
- MeSH terms
- Adrenal Gland Neoplasms, Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. https://app.cochat.ai/papers/10.1210/clinem/dgac379
- The paper
- Braun, L. T., Vogel, F., Zopp, S., Marchant Seiter, T., Rubinstein, G., Berr, C. M., Künzel, H., Beuschlein, F., & Reincke, M. (2022). Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

